New hope for head and neck cancer: which drug works best with radiation?
NCT ID NCT07441681
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation therapy. The goal is to see which approach better delays cancer growth and improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE I HPV-MEDIATED (P16-POSITIVE) OROPHARYNGEAL CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- A gentler path after surgery for HPV throat cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?